Study of CM310 in Adolescent Subjects With Atopic Dermatis

A Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of CM310 in Adolescent Patients With Atopic Dermatitis

This is a multi-center, single arm, open label phase 3 study to evaluate the safety and efficacy of CM310 in children patients with moderate-to-severe atopic dermatitis.

Inclusion Criteria:

• Have the ability to understand the study and voluntarily sign a written informed consent form (ICF).
• Subjects who must complete the evaluation of Week 18 of the main study.
• With Atopic Dermatitis.

Exclusion Criteria:

• Any major surgery planned during the research period.
• Subjects with potential fertility do not agree to adopt efficient contraceptive measures throughout the entire study period; Pregnant or breastfeeding women, or women planning to conceive or breastfeed during the study period.
• With any circumstance that the subject is not suitable to participate in this study.